[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Zhang, Z.M., Lai, E.C., Zhang, C., et al. (2015) The Strategies for Treating Primary Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. International Journal of Surgery, 20, 8-16. https://doi.org/10.1016/j.ijsu.2015.05.009
|
[3]
|
Llovet, J.M., Bustamante, J., Castells, A., et al. (1999) Natural His-tory of Untreated Nonsurgical Hepatocellular Carcinoma: Rationale for the Design and Evaluation of Therapeutic Trials. Hepatology, 29, 62-67.
https://doi.org/10.1002/hep.510290145
|
[4]
|
EASL (2018) Clinical Practice Guidelines: Management of Hepatocel-lular Carcinoma. Journal of Hepatology, 69, 182-236. https://doi.org/10.1016/j.jhep.2018.03.019
|
[5]
|
Omata, M., Cheng, A.L., Kokudo, N., et al. (2017) Asia-Pacific Clinical Practice Guidelines on the Management of Hepatocellular-carcinoma: A 2017 Update. Hepatology International, 11, 317-370.
https://doi.org/10.1007/s12072-017-9799-9
|
[6]
|
Kudo, M., Kawamura, Y., Hasegawa, K., et al. (2021) Manage-ment of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Can-cer, 10, 181-223. https://doi.org/10.1159/000514174
|
[7]
|
覃夏, 陈建发. 肝癌合并门静脉癌栓治疗的研究进展[J]. 广东医科大学学报, 2021, 39(4): 505-510.
|
[8]
|
Tan, Z.B. and Zhang, J. (2023) Recent Advances in Treatment Strategies for Hepatocellular Carcinoma with Portal Vein Cancer Thrombus. European Review for Medical and Phar-macological Sciences, 27, 8119-8134.
|
[9]
|
Ikai, I., Yamamoto, Y., Yamamoto, N., et al. (2003) Results of Hepatic Re-section for Hepatocellular Carcinoma Invading Major Portal and/or Hepatic Veins. Surgical Oncology Clinics of North America, 12, 65-75.
https://doi.org/10.1016/S1055-3207(02)00082-0
|
[10]
|
Cheng, S.Q., et al. (2007) Tumor Thrombus Types Influence the Prognosis of Hepatocellular Carcinoma with the Tumor Thrombi in the Portal Vein. Hepatogastroenterology, 54, 499-502.
|
[11]
|
Sun, J., Guo, R., Bi, X., et al. (2022) Guidelines for Diagnosis and Treatment of Hepatocellular Carcino-ma with Portal Vein Tumor Thrombus in China (2021 Edition). Liver Cancer, 11, 315-328. https://doi.org/10.1159/000523997
|
[12]
|
Chok, K.S., Cheung, T.T., Chan, S.C., et al. (2014) Surgical Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Tumorthrombosis. World Journal of Surgery, 38, 490-496. https://doi.org/10.1007/s00268-013-2290-4
|
[13]
|
中国医师协会肝癌专业委员会. 中国肝细胞癌合并门静脉癌栓诊疗指南(2021年版) [J]. 中华医学杂志, 2022, 102(4): 243-254.
|
[14]
|
Lee, J.M., Jang, B.K., Lee, Y.J., et al. (2016) Survival Outcomes of Hepatic Resection Compared with Transarterial Chemoembolization or Sorafenib for Hepatocellu-lar Carcinoma with Portal Vein Tumor Thrombosis. Clinical and Molecular Hepatology, 22, 160-167. https://doi.org/10.3350/cmh.2016.22.1.160
|
[15]
|
Chen, J., Lai, L., Zhou, C., et al. (2023) Safety, Efficacy, and Sur-vival of Drug-Eluting Beads-Transarterialchemoem- bolization vs. Conventional-Transarterial Chemoembolization in Advanced HCC Patients with Main Portalvein Tumor Thrombus. Cancer Imaging, 23, 70. https://doi.org/10.1186/s40644-023-00581-8
|
[16]
|
Chen, J., Lai, L., Luo, J., et al. (2022) DEM-TACE as the Initial Treatment Could Improve the Clinical Efficacy of the Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective Controlled Study. BMC Cancer, 22, Article No. 1242. https://doi.org/10.1186/s12885-022-10361-5
|
[17]
|
Hu, J., Bao, Q., Cao, G., et al. (2020) Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin plus 5-Fluorouracil versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis. CardioVascular and In-terventional Radiology, 43, 996-1005.
https://doi.org/10.1007/s00270-019-02406-3
|
[18]
|
Wu, Z., Gao, J., Zhuang, W., et al. (2022) Efficacy and Safety of Transcatheter Arterial Chemoembolization plus Hepatic Arterial Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis in the Main Trunk. Journal of Cancer Research and Therapeutics, 18, 345-351.
https://doi.org/10.4103/jcrt.jcrt_1078_21
|
[19]
|
曹洪祥, 黄平. 肝细胞癌合并门静脉癌栓的治疗现状[J]. 肝胆胰外科杂志, 2023, 35(4): 252-256.
|
[20]
|
Im, J.H., Yoon, S.M., Park, H.C., et al. (2017) Radiotherapeutic Strategies for Hepatocellular Carcinoma with Portal Vein Tumour Thrombosis in a Hepatitis B Endemic Area. Liver International, 37, 90-100.
https://doi.org/10.1111/liv.13191
|
[21]
|
Luo, J.J., Zhang, Z.H., Liu, Q.X., et al. (2016) Endovascular Brachytherapy Combined with Stent Placement and TACE for Treatment of HCC with Main Portal Vein Tumor Thrombus. Hepatology International, 10, 185-195.
https://doi.org/10.1007/s12072-015-9663-8
|
[22]
|
周冰莹, 安春娜, 蒲小平. 酪氨酸激酶抑制剂类新药的研发现状[J]. 中国新药杂志, 2011, 20(17): 1661-1666.
|
[23]
|
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版) [J]. 中华消化外科杂志, 2022, 21(2): 143-168.
|
[24]
|
Yuan, J., Yin, X., Tang, B., et al. (2019) Transarterial Chemoembolization (TACE) Combined with Sorafenib in Treatment of HBV Background Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score Matching Study. BioMed Research International, 2019, Article ID: 2141859. https://doi.org/10.1155/2019/2141859
|
[25]
|
Abulimiti, M., Li, Z., Wang, H., et al. (2021) Combination Intensity-Modulated Radiotherapy and Sorafenib Improves Outcomes in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Journal of Oncology, 2021, Article ID: 9943683. https://doi.org/10.1155/2021/9943683
|
[26]
|
Zheng, K., Zhu, X., Fu, S., et al. (2022) Sorafenib plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial. Radiology, 303, 455-464.
https://doi.org/10.1148/radiol.211545
|
[27]
|
Finn, R.S., Qin, S., Ikeda, M., et al. (2020) Atezolizumab plus Bevaci-zumab in Unresectable Hepatocellular Carcinoma. The New England Journal of Medicine, 382, 1894-1905. https://doi.org/10.1056/NEJMoa1915745
|
[28]
|
Li, N., Feng, S., Xue, J., et al. (2016) Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombus: A Comparative Study Comparing Hepatectomy with or without Neoadjuvant Radiotherapy. HPB (Oxford), 18, 549-556.
https://doi.org/10.1016/j.hpb.2016.04.003
|
[29]
|
Wei, X., Jiang, Y., Zhang, X., et al. (2019) Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study. Journal of Clinical Oncology, 37, 2141-2151. https://doi.org/10.1200/JCO.18.02184
|
[30]
|
Kamiyama, T., Nakanishi, K., Yokoo, H., et al. (2007) Efficacy of Preoperative Radiotherapy to Portal Vein Tumor Thrombus in the Main Trunk or First Branch in Patients with Hepato-cellular Carcinoma. International Journal of Clinical Oncology, 12, 363-368. https://doi.org/10.1007/s10147-007-0701-y
|
[31]
|
Wei, Z., Zhao, J., Bi, X., et al. (2022) Neoadjuvant Radiotherapy for Resectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Systematic Review. Hepatobiliary Sur-gery and Nutrition, 11, 709-717.
https://doi.org/10.21037/hbsn-20-854
|
[32]
|
Peng, B.G., He, Q., Li, J.P., et al. (2009) Adjuvant Transcatheter Arte-rial Chemoembolization Improves Efficacy of Hepatectomy for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus. The American Journal of Surgery, 198, 313-318. https://doi.org/10.1016/j.amjsurg.2008.09.026
|
[33]
|
Liu, F., Guo, X., Dong, W., et al. (2020) Postoperative Adju-vant TACE-Associated Nomogram for Predicting the Prognosis of Resectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus after Liver Resection. International Journal of Biological Sciences, 16, 3210-3220. https://doi.org/10.7150/ijbs.46896
|
[34]
|
Yuan, L., Feng, J., Zhang, Y., et al. (2023) Transarterial Chemoemboliza-tion plus Immune Checkpoint Inhibitor as Postoperative Adjuvant Therapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Cohort Study. European Journal of Surgical Oncology, 49, 1226-1233. https://doi.org/10.1016/j.ejso.2023.01.020
|
[35]
|
Sun, J., Yang, L., Shi, J., et al. (2019) Postoperative Adjuvant IMRT for Patients with HCC and Portal Vein Tumor Thrombus: An Open-Label Randomized Controlled Trial. Radio-therapy and Oncology, 140, 20-25.
https://doi.org/10.1016/j.radonc.2019.05.006
|
[36]
|
Hatano, E., Uemoto, S., Yamaue, H., et al. (2018) Significance of Hepatic Resection and Adjuvant Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in the First Branch of Portal Vein and the Main Portal Trunk: A Project Study for Hepatic Sur-gery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Journal of Hepato-Biliary-Pancreatic Sciences, 25, 395-402. https://doi.org/10.1002/jhbp.574
|
[37]
|
Zhu, K., Chen, J., Lai, L., et al. (2014) Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Treatment with Transarterial Chemoembolization Combined with Sorafenib—A Ret-rospective Controlled Study. Radiology, 272, 284-293. https://doi.org/10.1148/radiol.14131946
|
[38]
|
Zhang, Y., Fan, W., Wang, Y., et al. (2015) Sorafenib with and without Transarterial Chemoembolization for Advanced Hepatocel-lular Carcinoma with Main Portal Vein Tumor Thrombosis: A Retrospective Analysis. Oncologist, 20, 1417-1424. https://doi.org/10.1634/theoncologist.2015-0196
|
[39]
|
Deng, J., Liao, Z. and Gao, J. (2023) Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis. Current Oncology, 30, 1243-1254. https://doi.org/10.3390/curroncol30010096
|
[40]
|
Yang, B., Jie, L., Yang, T., et al. (2021) TACE plus Lenvatinib versus TACE plus Sorafenib for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Prospec-tive Cohort Study. Frontiers in Oncology, 11, Article ID: 821599. https://doi.org/10.3389/fonc.2021.821599
|
[41]
|
Ding, X., Sun, W., Li, W., et al. (2021) Transarterial Chemoembo-lization plus Lenvatinib versus Transarterial Chemoembolization plus Sorafenib as First-Line Treatment for Hepatocellu-lar Carcinoma with Portal Vein Tumor Thrombus: A Prospective Randomized Study. Cancer, 127, 3782-3793. https://doi.org/10.1002/cncr.33677
|
[42]
|
Xia, W.L., Zhao, X.H., Guo, Y., et al. (2023) Transarterial Chemoemboli-zation Combined with Apatinib plus PD-1 Inhibitors for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study. Clinical and Translational Gastroenterology, 14, e581. https://doi.org/10.14309/ctg.0000000000000581
|
[43]
|
Zou, X., Xu, Q., You, R., et al. (2023) Correlation and Effi-cacy of TACE Combined with Lenvatinib plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Based on Immunological Features. Cancer Medicine, 12, 11315-11333. https://doi.org/10.1002/cam4.5841
|
[44]
|
Chen, S., Yuan, B., Yu, W., et al. (2022) Hepatic Arterial Infusion Oxali-platin plus Raltitrexed and Chemoembolization in Hepatocellular Carcinoma with Portal Vein Invasion: A Propensity Score-Matching Cohort Study. Journal of Surgical Oncology, 126, 1205-1214. https://doi.org/10.1002/jso.27023
|
[45]
|
Liu, B.J., Gao, S., Zhu, X., et al. (2021) Combination Therapy of Che-moembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis. BioMed Research In-ternational, 2021, Article ID: 6670367.
https://doi.org/10.1155/2021/6670367
|
[46]
|
Choi, J.H., Chung, W.J., Bae, S.H., et al. (2018) Randomized, Pro-spective, Comparative Study on the Effects and Safety of Sorafenib vs. Hepatic Arterial Infusion Chemotherapy in Pa-tients with Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancer Chemotherapy and Phar-macology, 82, 469-478.
https://doi.org/10.1007/s00280-018-3638-0
|
[47]
|
Moriguchi, M., Aramaki, T., Nishiofuku, H., et al. (2017) Soraf-enib versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular Carcinoma with Advanced Portal Vein Tumor Thrombosis. Liver Cancer, 6, 275-286. https://doi.org/10.1159/000473887
|
[48]
|
He, M., Li, Q., Zou, R., et al. (2019) Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma with Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncology, 5, 953-960. https://doi.org/10.1001/jamaoncol.2019.0250
|
[49]
|
Yuan, Y., He, W., Yang, Z., et al. (2023) TACE-HAIC Combined with Targeted Therapy and Immunotherapy versus TACE Alone for Hepatocellular Carcinoma with Portal Vein Tumour Thrombus: A Propensity Score Matching Study. International Journal of Surgery, 109, 1222-1230. https://doi.org/10.1097/JS9.0000000000000256
|
[50]
|
Hu, Y., Zhou, M., Tang, J., et al. (2023) Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Clinical Cancer Research, 29, 4088-4097. https://doi.org/10.1158/1078-0432.CCR-22-2592
|
[51]
|
Zhao, X.H., Yuan, H., Xia, W.L., et al. (2022) Prospective Study of TACE Combined with Sorafenib vs TACE Combined with 125I Seed Implantation in the Treatment of Hepato-cellular Carcinoma with Portal Vein Tumor Thrombus and Arterioportal Fistulas. Frontiers in Oncology, 12, Article ID: 977462. https://doi.org/10.3389/fonc.2022.977462
|
[52]
|
Su, K., Gu, T., Xu, K., et al. (2022) Gamma Knife Radio-surgery versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Throm-bus: A Propensity Score Matching Study. Hepatology International, 16, 858-867. https://doi.org/10.1007/s12072-022-10339-2
|
[53]
|
Yoon, S.M., Ryoo, B.Y., Lee, S.J., et al. (2018) Efficacy and Safety of Transarterial Chemoembolization plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncology, 4, 661-669. https://doi.org/10.1001/jamaoncol.2017.5847
|
[54]
|
Lu, D., Tang, J., Zhou, J., et al. (2015) Clinical Control of Dif-ferent Sequential Order of Three-Dimensional Conformal Radiotherapy Combined with Transcatheter Arterial Che-moembolization for Portal Vein Tumor Thrombus in Patients with Hepatocellular Carcinoma. Chinese Journal of Hepa-tology, 23, 184-188.
|
[55]
|
Li, X., Guo, W., Guo, L., et al. (2018) Should Transarterial Chemoembolization Be Given be-fore or after Intensity-Modulated Radiotherapy to Treat Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus? A Propensity Score Matching Study. Oncotarget, 9, 24537-24547. https://doi.org/10.18632/oncotarget.25224
|
[56]
|
Ji, X., Xu, Z., Sun, J., et al. (2023) Lenvatinib with or without Ste-reotactic Body Radiotherapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Retrospective Study. Radiation Oncology, 18, Article No. 101.
https://doi.org/10.1186/s13014-023-02270-z
|
[57]
|
Hu, H.T., Luo, J.P., Cao, G.S., et al. (2021) Hepatocellular Car-cinoma with Portal Vein Tumor Thrombus Treated with Transarterial Chemoembolization and Sorafenib vs. 125Iodine Implantation. Frontiers in Oncology, 11, Article ID: 806907. https://doi.org/10.3389/fonc.2021.806907
|
[58]
|
Wu, Y.F., Wang, T., Yue, Z.D., et al. (2018) Stents Combined with Iodine-125 Implantation to Treat Main Portal Vein Tumor Thrombus. World Journal of Gastrointestinal Oncology, 10, 496-504. https://doi.org/10.4251/wjgo.v10.i12.496
|
[59]
|
Lu, J., Guo, J.H., Ji, J.S., et al. (2023) Irradiation Stent with 125I plus TACE versus Sorafenib plus TACE for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Multicenter Randomized Trial. International Journal of Surgery, 109, 1188-1198. https://doi.org/10.1097/JS9.0000000000000295
|
[60]
|
Ren, Z., Xu, J., Bai, Y., et al. (2021) Sintilimab plus a Bevacizumab Biosimilar (IBI305) versus Sorafenib in Unresectable Hepatocellular Carcinoma (ORIENT-32): A Ran-domised, Open-Label, Phase 2-3 Study. The Lancet Oncology, 22, 977-990. https://doi.org/10.1016/S1470-2045(21)00252-7
|
[61]
|
Lee, S.K., Kwon, J.H., Lee, S.W., et al. (2023) A Re-al-World Comparative Analysis of Atezolizumab plus Bevacizumab and Transarterial Chemoembolization plus Radio-therapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis. Cancers (Basel), 15, Article No. 4423. https://doi.org/10.3390/cancers15174423
|
[62]
|
Feng, J.K., Liu, Z.H., Fu, Z.G., et al. (2022) Efficacy and Safety of Transarterial Chemoembolization plus Antiangiogenic-Targeted Therapy and Immune Checkpoint Inhibitors for Unresec-table Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in the Real World. Frontiers in Oncology, 12, Article ID: 954203.
https://doi.org/10.3389/fonc.2022.954203
|